Reports
Published: 2026-05-28 07:00:00
Copenhagen, Denmark, 28 May 2026 - Curasight A/S (TICKER: CURAS) a clinical-stage radiopharmaceutical company pioneering first-in-class uPAR-targeted radioligand platform therapies across multiple aggressive solid tumors, hereby publishes the interim report Q1 2026. The interim report is available as an attached file to this release and on the Company''s website. Below is a summary of the report.
Curasight’s CEO Ulrich Krasilnikoff comments:
"Q1 2026 marked continued progress across both our therapeutic uTREAT® and diagnostic uTRACE® platforms as we advanced our integrated theranostic strategy targeting uPAR. During the quarter, we announced encouraging preliminary data from the ongoing Phase 1 trial evaluating uTREAT® in patients with high-grade gliomas, supporting the potential of our first-in-class radiopharmaceutical therapy platform in aggressive cancers with significant unmet medical need. We also increased Curasight’s international visibility through participation at the J.P. Morgan Healthcare Conference Week and TD Cowen’s 46th Annual Health Care Conference in Boston. Looking ahead, we remain focused on disciplined clinical execution and delivery of important milestones across both uTREAT® and uTRACE® during 2026."
Q1 (2026-01-01 – 2026-03-31)
• Gross loss amounted to kDKK -13,078 (kDKK -4,699)
• Operating loss amounted to kDKK -15,278 (kDKK -6,209)
• Loss before tax amounted to kDKK -16,704 (kDKK -6,579)
• Loss for the period amounted to kDKK -15,329 (kDKK -5,204)
• Total assets amounted to kDKK 36,246 (kDKK 17,660)
• Equity ratio amounted to 19.0% (14.2%)
• Earnings per share amounted to DKK -0.32 (DKK -0.25)
Numbers in parenthesis are the numbers from the same period in 2025.
About Curasight A/S
Curasight is advancing uTREAT®, a clinical-stage, first-in-class uPAR-targeted radioligand therapy (RLT) designed to treat solid tumors. uTREAT® targets uPAR, a key driver of tumor invasion, angiogenesis, and metastasis, which is expressed in more than 85% of solid tumors. The company’s theranostic platform also includes uTRACE®, a uPAR-PET imaging agent built on the same proprietary ligand as uTREAT®. uTRACE® supports patient selection and confirms tumor targeting and has been evaluated in more than 450 patients across nine Phase II trials in eight solid tumor indications. The uPAR platform is based on more than a decade of research at the Copenhagen University Hospital and the University of Copenhagen.
For more information regarding Curasight, please contact:
Ulrich Krasilnikoff, CEO
E-mail: uk@curasight.com
